Smith & Nephew Share Discussion Threads

[nscap] 09/3/2009 10:18

Excellent company. Price target of 580p by september.

Long 10,000 @ 448

[mitzis] 18/2/2009 17:03

New broker target of 618p..

[fast investor] 12/2/2009 08:15

Excelent full year results from this company this morning..

Smith & Nephew reports steady growth
press association

Smith & Nephew today reported underlying group reovenue up 7% in Q4. Orthopaedics revenues increased by 6%, reflecting a strong US performance and Endoscopy delivered another good result growing revenues by 9%.

Advanced Wound Management grew revenues by 7%, driven by a strong European and rest of the world performance.

Trading margin of 23.2%, marginally up on last year, was impacted by NPWT investment, Plus and compliance costs.

EPS was maintained at 16.6 cents.

For the full-year, group revenue was up 13% to $3.8bn, with underlying growth of 6%.

Trading profit was up 10% to $776m, up 6% underlying.

EPS increased 7% to 55.6 cents.

Orthopaedics revenues grew at 5% (8% excluding Plus impact4), while Endoscopy finished the year with 8% growth.

Advanced Wound Management, at 7% growth, delivered its best growth performance for 5 years

Trading margin at 20.4%, masking the longer term operating efficiency improvements we have made to our businesses

The group increased the second interim dividend by 10% to 8.12 cents per share.

Commenting on the full year, David Illingworth, CEO, said: 'We finished the year in a positive frame of mind. We grew underlying sales for the year by 6%, with a similar increase in trading profit. All of our businesses reported underlying sales growth. These achievements are particularly notable against the backdrop of the slowdown in the global economy and a number of industry-wide and company specific issues.

We remain alert to any changes in the near-term outlook in our businesses and believe that our company-wide Earnings Improvement Programme, which we started two years ago, gives us a head start in dealing with any tougher operating climate.

We are focused on extending our track record of delivering innovative products, bringing clinical benefits to patients and economic benefits to healthcare providers. We put our customers first, listen to their needs and deliver on our promises. The Board has continued its policy of increasing, by 10%, the dividend which is declared in US dollars, creating a significant additional benefit for sterling-based shareholders. I am confident we will continue to deliver sustainable long-term growth for our shareholders.'

[fast investor] 09/2/2009 11:59

Recent broker analysis ahead of results..

29.01.09 :-23.25, (481.25) Goldman Sachs upgrades the medical device company to "buy" from "neutral" and adds it to its "conviction buy" list. "Smith & Nephew's status as the cheapest European medtech stock on 2009 P/E is out of line with robust 6 percent organic sales growth and 8 percent cash EPS growth 2008-10," the broker says in a note. "Its recent de-rating fails to discount the major FX benefit from the near 30 percent depreciation of sterling from its hugely international business. While our view remains that the rate of margin improvemnet will fall short of guidance, we consider this overdone in its current valuation."

[romi2nikki1] 05/2/2009 13:40

Should be a few fractures this winter.

[bangers] 04/2/2009 14:31

nice breakout

[ducatiman] 21/11/2008 15:57

buying territory?

[roughjustice] 22/8/2008 19:24

Recommended as a tip on - Ninth Episode

[like2share] 20/8/2008 06:45

From thisismoney.co.uk 'Perennial takeover favourite Smith & Nephew was one of the few stocks sparking their interest and diverting eyes away from Britain's gold medal haul in Beijing. Talk of a bid for the artificial joints maker and its defensive nature, sent it racing to the top of the Footsie leaderboard, climbing 13½p to 632p.

US group Zimmer is thought to be eyeing up its UK rival, with traders noting that its recent strong results and the rally in the US dollar have made Smith appear desirable.'

Good for the sector, CRG results next Thursday.

[boadicea] 07/8/2008 14:30

I hadn't noticed that interims were expected today - Anyway, pleasant reading and a good share price rise to go with it.
I suggest you get the script from here, rather than the garbled advfn version -


Just enter 'sn.' on the top line (and specify 'this week' etc if not today)

[a_zimbo] 05/6/2008 10:12

Or Bristol Myers:

[funkey n] 05/6/2008 08:50

This is from SVS Securities
Smith & Nephew (rumours of a 700 pence a share bid from a Japanese medical devices group),

[boadicea] 05/6/2008 08:46

Interesting to note that the share price recovery is taking place while the company has stopped (presumably completed) its stock buy-in programme.
In the absence of obvious trading stimulus and generally against the background market sentiment, one assumes the movement is speculative or caused by those who know something we don't - the elusive insider trading that is never proved.

[barker haines] 04/6/2008 17:50

Up 3.8% today. Be interesting to see what happens tomorrow. May dip in as my average is 625p.

[jhs001] 04/6/2008 13:01

2 strong moves 03 and 04 June but no news. Anyone have any ideas what's going on?

[liquidkid] 15/5/2008 10:21

That Cormet news, that sales will be low in 08 is supposed to be good news for S&N But it goes down anyway.

[scrapman] 13/5/2008 16:02

back to Jan 07 prices now ,

[paul140352] 13/5/2008 15:27

Yes, a sort of lop sided double bottom has formed !

[paulw2] 12/5/2008 09:33

looks like it's on the way up now.

[phillis] 12/5/2008 09:09

Time to get back in

[paul140352] 09/5/2008 12:08

Good to buy now. Nice bounce has began. I am long from 556, can see 650 in a week or so, good defensive stock. imho. dyor.

[bish100] 06/5/2008 11:49

If the graph says so - short it!!!!

[h4rsh2] 06/5/2008 11:20

bish.. the graph says next support is £5.00..

[bish100] 06/5/2008 09:18

My comment is within weeks - trying to predict day on day is impossible. Even better value!!